Chromosomal instability refers to mutations in a person's DNA
that means whole chromosomes or parts of chromosomes are duplicated
or deleted. This is usually linked to poor treatment outcome
in cancer - but Francis Crick Institute researchers have shown in a
large validation study that in some breast cancers, extreme
chromosomal instability is actually associated with improved
outcomes.
Professor Charles Swanton of the Crick (currently based at Lincoln's Inn Fields) said: "Many studies have shown that
chromosomal instability is associated with poor response to
treatment and poor outcome."
Professor Swanton's team investigated chromosomal instability in
over 1,000 samples from breast cancer tumours by looking at two
chromosomes that are not usually linked to chromosomal instability
in breast cancer.
They found that in patients with a type called oestrogen
receptor (ER)-negative breast cancer, which accounts for around a
third of patients, extreme chromosomal instability was linked to
better outcomes. The outcome measured was disease-free survival,
which is the length of time after treatment a patient survives
without any sign of the cancer coming back. This paradoxical
link was previously shown in a small group of patients, and so the
purpose of this study was to validate this link using a much larger
group of patients. This is the largest study looking at the link
between chromosomal instability and outcome in breast
cancer.
Speculating on the reasons for their finding, the scientists
suggest that extreme chromosomal instability might be self-limiting
and reduce a tumour's ability to keep growing. This could mean that
certain drugs, such as those that damage DNA, might be able to
increase the level of chromosomal instability in a tumour and
therefore improve outcome.
Dr Mariam Jamal-Hanjani of the Crick said: "This finding is
important since it highlights the potential value in using
chromosomal instability as an indicator of prognosis in ER-negative
breast cancer. Identifying patients with extreme chromosomal
instability may help distinguish those who have a good prognosis
from those who don't, and help in making decisions about
treatment."
The paper, Extreme chromosomal instability forecasts improved outcome in
ER-negative breast cancer: a prospective validation cohort study
from the TACT trial, is published in the Annals of
Oncology.